Markus Rose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The vaccine RSVpreF had an almost 82% efficacy against severe RSV infection in infants from birth through the first 90 days of life, according to company data.

Thomas mertensOrtwin adamsMarkus roseScience media centerInstitute for virology at ulm university hospitalInstitute for virology of the university hospitalDrug administrationData monitoring committeeStanding committee on vaccinationRobert koch instituteUniversity hospitalPediatric pulmonologyStanding committeeUlm university hospitalPrefusionf specificCombined tdap vaccine